ARIPIPRAZOLE IN TOURETTE'S DISORDER AND EXPLOSIVE OUTBURSTS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究假设，阿立哌唑，已被证明是有效的治疗精神病和躁狂抑郁症，将比安慰剂更有效地降低儿童和青少年的抽动秽语障碍（TD）的爆发性发作的严重程度，通过测量的频率，强度和持续时间的爆发性发作。 该研究将测试一种相对安全的药物用于成人治疗儿童和青少年TD的疗效和安全性。 终点是由工作人员进行的各种不同的神经精神测试，这些测试将测量抽搐、频率、愤怒、范围和爆发。 一个新设计的测试，愤怒严重程度量表，将管理，并在此规模上测量的治疗效果将比较更传统的评估。 该研究是一项为期6周的安慰剂对照试验，与安慰剂相比，阿立哌唑的剂量增加。 计划治疗组和安慰剂组各15人，因为早期信息表明，使用少量治疗个体，该药物对TD有非常显著的影响（p<10-12）。 将纵向评估人内变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study hypothesizes that aripiprazole, which has been shown to be effective in the treatment of psychotic and manic-depressive disorders, will be more effective than placebo in reducing the severity of explosive outbursts in children and adolescents with Tourette's Disorder (TD), as assessed by measuring the frequency, intensity, and duration of explosive outbursts. The study will test the efficacy and safety of a relatively safe drug when used in adults as a treatment of TD in children and adolescents. The endpoints are a variety of different neuropsychiatric tests, administered by the staff, that will measure tic, frequency, anger, range, and outbursts. A newly devised test, the Rage Severity Scale, will be administered, and the effects of treatment measured on this scale will be compared to more traditional assessments. The study is a placebo-controlled, 6-week trial with increasing doses of aripiprazole versus placebo. Treatment and placebo groups of 15 are planned, as early information suggests a very significant impact of this drug in TD (p<10-12) using a small number of treated individuals. Within-person changes will be assessed longitudinally.